Table 2 Breast cancer characteristics by tumor marker status: EPIC-Heidelberg nested case-control study
All cases | CYP27A1 | CYP7B1 | LXR-β | ERβ | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Negative | Positive | pa | Negative | Positive | pa | Negative | Positive | pa | Negative | Positive | pa | ||
N | 287 | 201 | 72 | 157 | 86 | 123 | 164 | 84 | 203 | ||||
Age at diagnosis | 58.84 ± 7.69 | 59.35 ± 8.81 | 0.71 | 59.22 ± 8.23 | 60.51 ± 7.66 | 0.28 | 58.76 ± 8.08 | 59.39 ± 8.01 | 0.57 | 60.12 ± 7.59 | 58.68 ± 8.20 | 0.22 | |
Receptor subtype | |||||||||||||
ER+ | 236 | 166 (83.0) | 58 (80.6) | 0.72 | 129 (82.2) | 74 (86.0) | 0.47 | 102 (82.9) | 134 (82.2) | 1.00 | 68 (81.0) | 168 (83.2) | 0.73 |
ER− | 50 | 34 (17.0) | 14 (19.4) | 28 (17.8) | 12 (14.0) | 21 (17.1) | 29 (17.8) | 16 (19.0) | 34 (16.8) | ||||
ER+/PR+ | 206 | 142 (82.6) | 52 (81.3) | 0.85 | 111 (81.0) | 69 (88.5) | 0.18 | 87 (82.9) | 119 (82.6) | 1.00 | 59 (80.8) | 147 (83.5) | 0.59 |
ER−/PR− | 43 | 30 (17.4) | 12 (18.8) | 26 (19.0) | 9 (11.5) | 18 (17.1) | 25 (17.4) | 14 (19.2) | 29 (16.5) | ||||
PR+ | 213 | 146 (73.0) | 54 (75.0) | 0.88 | 113 (72.0) | 72 (83.7) | 0.04 | 90 (73.2) | 123 (75.5) | 0.68 | 61 (72.6) | 152 (75.2) | 0.66 |
PR− | 73 | 54 (27.0) | 18 (25.0) | 44 (28.0) | 14 (16.3) | 33 (26.8) | 40 (24.5) | 23 (27.4) | 50 (24.8) | ||||
HER2+ | 46 | 36 (18.0) | 9 (12.5) | 0.36 | 26 (16.6) | 14 (16.3) | 1.00 | 19 (15.4) | 27 (16.6) | 0.87 | 14 (16.7) | 32 (15.8) | 0.86 |
HER2− | 240 | 164 (82.0) | 63 (87.5) | 131 (83.4) | 72 (83.7) | 104 (84.6) | 136 (83.4) | 70 (83.3) | 170 (84.2) | ||||
ER−/PR−/HER2− | 31 | 19 (9.5) | 11 (15.3) | 0.19 | 17 (10.8) | 6 (7.0) | 0.21 | 12 (9.8) | 19 (11.7) | 0.70 | 9 (10.7) | 22 (10.9) | 1.00 |
ER+ or PR+ or HER2+ | 255 | 181 (90.5) | 61 (84.7) | 140 (89.2) | 80 (93.0) | 111 (90.2) | 144 (88.3) | 75 (89.3) | 180 (89.1) | ||||
Ki67 | |||||||||||||
Low | 46 | 34 (17.7) | 12 (18.5) | 0.85 | 23 (16.3) | 8 (9.6) | 0.23 | 15 (14.0) | 31 (19.6) | 0.25 | 11 (15.1) | 35 (18.2) | 0.59 |
High | 219 | 158 (82.3) | 53 (81.5) | 118 (83.7) | 75 (90.4) | 92 (86.0) | 127 (80.4) | 62 (84.9) | 157 (81.8) | ||||
bcl2 | |||||||||||||
Low | 165 | 121 (62.7) | 40 (59.7) | 0.66 | 79 (56.4) | 54 (64.3) | 0.26 | 71 (64.5) | 94 (60.3) | 0.52 | 35 (49.3) | 130 (66.7) | 0.01 |
High | 101 | 72 (37.3) | 27 (40.3) | 61 (43.6) | 30 (35.7) | 39 (35.5) | 62 (39.7) | 36 (50.7) | 65 (33.3) | ||||
p53 | |||||||||||||
Low | 52 | 43 (22.4) | 8 (11.6) | 0.05 | 31 (22.0) | 12 (14.3) | 0.17 | 19 (17.6) | 33 (20.9) | 0.53 | 13 (18.3) | 39 (20.0) | 0.86 |
High | 214 | 149 (77.6) | 61 (88.4) | 110 (78.0) | 72 (85.7) | 89 (82.4) | 125 (79.1) | 58 (81.7) | 156 (80.0) | ||||
Breast cancer stage | |||||||||||||
Local | 175 | 119 (61.0) | 44 (61.1) | 0.46 | 94 (60.6) | 56 (68.3) | 0.53 | 82 (67.2) | 93 (58.5) | 0.12 | 43 (53.1) | 132 (66.0) | 0.07 |
Regional | 100 | 73 (37.4) | 25 (34.7) | 57 (36.8) | 25 (30.5) | 36 (29.5) | 64 (40.3) | 35 (43.2) | 65 (32.5) | ||||
Metastasis | 6 | 3 (1.5) | 3 (4.2) | 4 (2.6) | 1 (1.2) | 4 (3.3) | 2 (1.3) | 3 (3.7) | 3 (1.5) | ||||
Breast cancer grade | |||||||||||||
Grade I | 38 | 30 (15.0) | 7 (9.9) | 0.41 | 21 (13.4) | 15 (17.6) | 0.64 | 18 (14.8) | 20 (12.3) | 0.06 | 7 (8.3) | 31 (15.4) | 0.28 |
Grade II | 163 | 114 (57.0) | 39 (54.9) | 87 (55.4) | 43 (50.6) | 77 (63.1) | 86 (52.8) | 50 (59.5) | 113 (56.2) | ||||
Grade III | 84 | 56 (28.0) | 25 (35.2) | 49 (31.2) | 27 (31.8) | 27 (22.1) | 57 (35.0) | 27 (32.1) | 57 (28.4) | ||||
Breast cancer morphology | |||||||||||||
Ductal | 202 | 142 (70.6) | 54 (75) | 0.19 | 109 (69.4) | 59 (68.6) | 0.68 | 83 (67.5) | 119 (72.6) | 0.21 | 61 (72.6) | 141 (69.5) | 0.48 |
Lobular | 56 | 36 (17.9) | 15 (20.8) | 29 (18.5) | 19 (22.1) | 23 (18.7) | 33 (20.1) | 13 (15.5) | 43 (21.2) | ||||
Other | 29 | 23 (11.4) | 3 (4.2) | 19 (12.1) | 8 (9.3) | 17 (13.8) | 12 (7.3) | 10 (11.9) | 19 (9.4) | ||||